Brief: SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program
26/09/2024 12:03
Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O :
* SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE
COLLABORATION
WITH BIOGEN ON THE SAGE-324 PROGRAM
* SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER
SAGE-324
PROGRAM
* SAGE THERAPEUTICS INC - TERMINATION EFFECTIVE FEBRUARY 17,
2025;
SAGE TO RESUME FULL OWNERSHIP OF SAGE-324
* SAGE THERAPEUTICS INC - TO EVALUATE OTHER POTENTIAL
INDICATIONS
FOR SAGE-324
Source text for Eikon: ID:nBw7ZShFxa
Further company coverage: SAGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview